Live Research Database

Real-world data is becoming increasingly important for pharmaceutical companies to assess the real-world value and efficacy of their drugs, as evidenced by Roche's $2 billion acquisition of Flatiron Health in 2018.² Our next core value feature is our live, ever-growing database of user health states, which includes over 90 longevity biomarkers, which can be used to assess the safety and efficacy of supplements and longevity treatments. The blockchain-based Rejuve ID ensures the identity of participants across their contributed datasets. Users are interested in becoming Data Commons contributors because they own their data and are compensated for it. This Data Commons will be a valuable tool and resource not only for evaluating the efficacy of existing treatments and protocols, but also for discovering new patterns and trends, as well as serving as an immediate source of participants for new studies and clinical trials.